Cargando…
The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations
Clostridium difficile infection (CDI) is associated with high mortality. Reducing incidence is a priority for patients, clinicians, the National Health Service (NHS) and Public Health England alike. In June 2012, fidaxomicin (FDX) was launched for the treatment of adults with CDI. The objective of t...
Autores principales: | Goldenberg, S. D., Brown, S., Edwards, L., Gnanarajah, D., Howard, P., Jenkins, D., Nayar, D., Pasztor, M., Oliver, S., Planche, T., Sandoe, J. A. T., Wade, P., Whitney, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724367/ https://www.ncbi.nlm.nih.gov/pubmed/26661400 http://dx.doi.org/10.1007/s10096-015-2538-z |
Ejemplares similares
-
Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012) -
Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015) -
A multi-center study of fidaxomicin use for Clostridium difficile infection
por: Shah, Dhara N., et al.
Publicado: (2016) -
Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013) -
Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)